Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) Director Charles Bramlage bought 1,800 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average price of $13.85 per share, with a total value of $24,930.00. Following the completion of the transaction, the director now directly owns 1,800 shares of the company’s stock, valued at approximately $24,930. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

BDSI has been the subject of a number of recent research reports. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $20.00 in a research note on Friday, August 8th. Separately, analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $21.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. BioDelivery Sciences International currently has a consensus rating of “Buy” and an average price target of $20.50.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded up 3.11% during mid-day trading on Monday, hitting $14.25. 1,380,890 shares of the company’s stock traded hands. BioDelivery Sciences International has a 52-week low of $4.16 and a 52-week high of $14.44. The stock has a 50-day moving average of $13.16 and a 200-day moving average of $10.34. The company’s market cap is $702.5 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Friday, August 15th. The company reported ($0.14) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.07. On average, analysts predict that BioDelivery Sciences International will post $-0.67 earnings per share for the current fiscal year.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.